U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C32H52N4O4.2Br
Molecular Weight 716.588
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEMECARIUM BROMIDE

SMILES

[Br-].[Br-].CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C

InChI

InChIKey=YHKBUDZECQDYBR-UHFFFAOYSA-L
InChI=1S/C32H52N4O4.2BrH/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8;;/h17-22,25-26H,9-16,23-24H2,1-8H3;2*1H/q+2;;/p-2

HIDE SMILES / InChI

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C32H52N4O4
Molecular Weight 556.7797
Charge 2
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00944

Demecarium (HUMORSOL®) is an indirect-acting parasympathomimetic agent, also known as a cholinesterase inhibitor and anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Application of demecarium (HUMORSOL®) to the eye produces intense miosis and ciliary muscle contraction due to inhibition of cholinesterase, allowing acetylcholine to accumulate at sites of cholinergic transmission. These effects are accompanied by increased capillary permeability of the ciliary body and iris, increased permeability of the blood-aqueous barrier, and vasodilation. Myopia may be induced or, if present, may be augmented by the increased refractive power of the lens that results from the accommodative effect of the drug. Demecarium (HUMORSOL®) indirectly produces some of the muscarinic and nicotinic effects of acetylcholine as quantities of the latter accumulate.

Originator

Curator's Comment: Schmid, O.; US. Patent 2,789,981; April 23, 1957; assigned to Chemie Linz Ag, Austria.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HUMORSOL

Approved Use

Open-angle glaucoma (HUMORSOL® should be used in glaucoma only when shorter-acting miotics have proved inadequate). Conditions obstructing aqueous outflow, such as synechial formation, that are amenable to miotic therapy. Following iridectomy. Accommodative esotropia (accommodative convergent strabismus).

Launch Date

-3.2849281E11
Palliative
HUMORSOL

Approved Use

Open-angle glaucoma (HUMORSOL® should be used in glaucoma only when shorter-acting miotics have proved inadequate). Conditions obstructing aqueous outflow, such as synechial formation, that are amenable to miotic therapy. Following iridectomy. Accommodative esotropia (accommodative convergent strabismus).

Launch Date

-3.2849281E11
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

For glaucoma initial therapy with demecarium (HUMORSOL®) place 1 or 2 drops in the glaucomatous eye. The usual dosage can vary from as much as 1 or 2 drops twice a day to as little as 1 or 2 drops twice a week. For treatment of esotropia with demecarium (HUMORSOL®) 1 drop is given daily for 2 weeks, then 1 drop every 2 days for 2 to 3 weeks. In esotropia uncomplicated by amblyopia or anisometropia, demecarium (HUMORSOL®) may be instilled in both eyes, not more than 1 drop at a time every day for 2 to 3 weeks, as too severe a degree of miosis may interfere with vision. Then reduce the dosage to 1 drop every other day for 3 to 4 weeks and reevaluate the patient's status.
Route of Administration: Topical
Tetramethoquin and demecarium bromide were compared with physostigmine on the hypogastric guinea-pig nerve-vas deferens preparation. Each drug, in bath concentrations of 1 ug/ml, potentiated the response of the vas deferens to nerve stimulation. Subsequent addition of a higher dose of these agents inhibited the response. With demecarium inhibition occurred with 3 to 5 ug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:48 UTC 2023
Edited
by admin
on Fri Dec 15 15:00:48 UTC 2023
Record UNII
61D5V4OKTP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEMECARIUM BROMIDE
HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
HUMORSOL
Brand Name English
DEMECARIUM BROMIDE [MART.]
Common Name English
DEMECARIUM BROMIDE [MI]
Common Name English
N,N'-BIS(3-TRIMETHYLAMMONIUMPHENOXYCARBONYL)-N,N'-DIMETHYLDECAMETHYLENEDIAMINE DIBROMIDE
Common Name English
DEMECARIUM BROMIDE [VANDF]
Common Name English
3,3'-(1,10-DECANEDIYLBIS((METHYLIMINO)CARBONYLOXY))BIS(N,N,N-TRIMETHYLBENZENAMINIUM)DIBROMIDE
Common Name English
(M-HYDROXYPHENYL)TRIMETHYLAMMONIUM BROMIDE DECAMETHYLENEBIS(METHYLCARBAMATE) (2:1)
Common Name English
DEMEKASTIGMINE BROMIDE
Common Name English
Demecarium bromide [WHO-DD]
Common Name English
DEMECARIUM BROMIDE [USP-RS]
Common Name English
DEMECARIUM BROMIDE [USP MONOGRAPH]
Common Name English
demecarium bromide [INN]
Common Name English
DEMECARIUM BROMIDE [ORANGE BOOK]
Common Name English
BENZENAMINIUM, 3,3'-(1,10-DECANEDIYLBIS((METHYLIMINO)CARBONYLOXY))BIS(N,N,N-TRIMETHYL-, DIBROMIDE
Common Name English
BC-48
Code English
DEMECARIUM BROMIDE [HSDB]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47792
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
NCI_THESAURUS C29705
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
Code System Code Type Description
FDA UNII
61D5V4OKTP
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
PUBCHEM
5965
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
WIKIPEDIA
DEMECARIUM BROMIDE
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
NCI_THESAURUS
C65367
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
CHEBI
4391
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-301-9
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
EVMPD
SUB06962MIG
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
CAS
56-94-0
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
EPA CompTox
DTXSID6045240
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
DRUG BANK
DB00944
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
INN
769
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
SMS_ID
100000083690
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
MERCK INDEX
m4159
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1201229
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
HSDB
2168
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
RXCUI
22482
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY RxNorm
DAILYMED
61D5V4OKTP
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
RS_ITEM_NUM
1169001
Created by admin on Fri Dec 15 15:00:49 UTC 2023 , Edited by admin on Fri Dec 15 15:00:49 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY